ORPHA:2690
Neutropenia-monocytopenia-deafness syndrome
Also known as: Neutropenia-monocytopenia-hearing loss syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
7
19.9th percentile
Trials
0
Interventional, condition-specific
Researchers
86
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare syndrome characterized by neutropenia with myeloid marrow hypoplasia, monocytopenia, and deafness. Patients present with severe recurrent bacterial infections that may lead to bacterial septicemia. There have been no further descriptions in the literature since 1983.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017100
- UMLS:C4518430
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
7 matched papers (5 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 327 for broader category neutropenia
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
7
7 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
7 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
5 in the last 10 years · high confidence · 19.9th percentile (publications denominator)
Phrase hits: 7 · MeSH hits: 0
Who's working on it?
86
Distinct author names in 7 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Yang Y2 papers · 2021
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA.
Papers in Europe PMC - 02Akarsu NA1 paper · 2017
Gene Mapping Laboratory, Department of Medical Genetics, Hacettepe University Medical Faculty, Sihhiye, Ankara, Turkey.
Papers in Europe PMC - 03Alghisi E1 paper · 2017
Department of Biomedicine, University Hospital Basel, University of Basel, Basel, Switzerland.
Papers in Europe PMC - 04Alsaleh G1 paper · 2017
Laboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, INSERM UMR - S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Papers in Europe PMC - 05Amati-Bonneau P1 paper · 2017
CNRS UMR 6015, INSERM UMR - S1083, MitoVasc Institute, Angers University, Angers, France.
Papers in Europe PMC - 06Aprikyan AA1 paper · 2009Papers in Europe PMC
- 07Arand J1 paper · 2002Papers in Europe PMC
- 08Asquith KL1 paper · 2022
School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, Australia.
Papers in Europe PMC - 09Bahram S1 paper · 2017
Laboratoire d'ImmunoRhumatologie Moléculaire, Plateforme GENOMAX, INSERM UMR - S1109, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.
Papers in Europe PMC - 10Barr I1 paper · 2022
WHO Collaborating Centre for Reference and Research on Influenza, The Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 327 trials are registered for neutropenia, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
327 interventional trials matched neutropenia, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: neutropenia
327
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06293677·RECRUITING·Adjustment of Antibiotic Dosage in Pediatric Oncology Patients With Febrile Neutropenia and Augmented Renal Clearance
Conditions: Febrile Neutropenia·Matched via name phrase
- NCT05537896·RECRUITING·Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Conditions: Hematological Malignancy · Neutropenia·Matched via name phrase
- NCT06135896·RECRUITING·Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers
Conditions: Unresectable Pancreatic Cancer · Unresectable Bile Duct Carcinoma · Unresectable Biliary Tract Carcinoma·Matched via name phrase
- NCT06988826·NOT YET RECRUITING·Comparison of G-CSF & Antibiotics Versus Antibiotics Alone in Resolution of Febrile Neutropenia
Conditions: Febrile Neutropenia · Febrile Neutropenia, Rule of Clinical Decision, Chemotherapy · Febrile Neutropenia, Drug-Induced · G-CSF·Matched via name phrase
- NCT06926751·RECRUITING·Telpegfilgrastim vs Filgrastim for Secondary Prevention of Chemotherapy-Induced Neutropenia in Pediatric Solid Tumors
Conditions: Solid Tumors · Children · Adolescent · Chemotherapy Induced Neutropenia·Matched via name phrase
- NCT05626530·RECRUITING·Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
Conditions: Cytomegalovirus Infections · Infection in Solid Organ Transplant Recipients · Neutropenia · Antiviral Toxicity·Matched via name phrase
- NCT07187908·RECRUITING·Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
Conditions: Primary/Secondary Prevention · High Risk for Febrile Neutropenia of Chemotherapy Regimens · Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia·Matched via name phrase
- NCT07047352·NOT YET RECRUITING·Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study)
Conditions: Carbapenem-resistant Enterobacterales · Neutropenia · Hematological Malignancies·Matched via name phrase
- NCT07071844·NOT YET RECRUITING·BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
Conditions: Metastatic Colorectal Cancer·Matched via name phrase
- NCT07300735·RECRUITING·Comparing Diosmin-Hesperidin and Loratadine to Prevent Bone Pain From G-CSF in Patients With Blood Cancers
Conditions: Hematologic Malignancy · Neutropenia · Bone Pain·Matched via name phrase
- NCT07066085·RECRUITING·Serial Blood Count Study
Conditions: Cyclic Neutropenia · Congenital Neutropenia · Neutropenia·Matched via name phrase
- NCT06649448·NOT YET RECRUITING·A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
Conditions: Solid Tumor Cancer · Chemotherapy Induced Neutropenia · G-CSF·Matched via name phrase
- NCT07578064·RECRUITING·A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
Conditions: Breast Cancer · Bone Marrow Suppression·Matched via name phrase
- NCT07018271·NOT YET RECRUITING·A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma Patients
Conditions: Multiple Myeloma · DRD · Sulpegfilgrastim · Neutropenia·Matched via name phrase
- NCT06616571·RECRUITING·Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints
Conditions: Chemotherapy-Induced Febrile Neutropenia·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Neutropenia-monocytopenia-deafness syndrome" OR "Neutropenia-monocytopenia-hearing loss syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Neutropenia-monocytopenia-deafness syndrome" OR "Neutropenia-monocytopenia-hearing loss syndrome" OR "constitutional neutropenia"
Recall-expansion terms: constitutional neutropenia
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"neutropenia"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T20:51:55.562Z
